Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

591
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
591
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

697
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
697
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.8K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

631
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

5.4K
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Remote actigraphy is seasonally variable with implications for clinical monitoring.

American journal of respiratory and critical care medicine·2026
Same author

Perioperative and oncologic outcomes of extirpative surgery for upper tract urothelial cancer in octogenarians.

Urologic oncology·2026
Same author

Anxiety, Depression, and Suicidality Among Testicular Cancer Survivors.

Cancer medicine·2026
Same author

Granular cell tumour of the breast: A rare mimic of breast carcinoma.

Ultrasound (Leeds, England)·2026
Same author

Genome Sequence of <i>Arthrobacter globiformis</i> B-2979 phage Ichiang.

microPublication biology·2025
Same author

Molecular Features and Actionable Gene Targets of Testicular Germ Cell Tumors in a Real-World Setting.

International journal of molecular sciences·2025
Same journal

Effective Mentorship in Urology Fellowship Training: Qualities, Models, and Equity.

Current urology reports·2026
Same journal

Management of Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis.

Current urology reports·2026
Same journal

Lower Urinary Tract Symptoms as an Indicator of Occult Neurologic Disease: A System-first Framework for Urologic Practice.

Current urology reports·2026
Same journal

Association Between Ambient Temperature and Urolithiasis: A Systematic Review and Meta-analysis.

Current urology reports·2026
Same journal

Is Open Partial Nephrectomy Still an Option in the Robotic Era?

Current urology reports·2026
Same journal

Artificial Intelligence in Urologic Documentation: A Review of Emerging Capabilities and the Ongoing Need for Human Oversight.

Current urology reports·2026
See all related articles

Related Experiment Video

Updated: Mar 21, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.8K

Phytotherapy for Benign Prostatic Hyperplasia.

Aryeh Keehn1, Jacob Taylor1, Franklin C Lowe2

  • 1Department of Urology, Albert Einstein College of Medicine, Bronx, NY, USA.

Current Urology Reports
|May 16, 2016
PubMed
Summary
This summary is machine-generated.

Phytotherapy for benign prostatic hyperplasia (BPH) shows no significant benefit over placebo. Despite market popularity, rigorous studies indicate these supplements are not more effective than a placebo for treating BPH symptoms.

Keywords:
BPHHypoxis rooperiPhytotherapyPygeum africanumSecale cerealeSeronoa repens

More Related Videos

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

20.5K
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.5K

Related Experiment Videos

Last Updated: Mar 21, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.8K
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

20.5K
Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser
07:17

Photoselective Vaporesection of the Prostate via an End-firing Lithium Triborate Crystal Laser

Published on: May 9, 2018

8.5K

Area of Science:

  • Urology
  • Pharmacology
  • Integrative Medicine

Background:

  • Benign prostatic hyperplasia (BPH) is a common condition affecting aging men.
  • Complementary and alternative medications for symptomatic BPH represent a significant market in the USA.
  • The efficacy of phytotherapy for BPH warrants investigation due to its widespread use.

Purpose of the Study:

  • To evaluate the scientific evidence supporting the use of phytotherapy for managing symptomatic benign prostatic hyperplasia (BPH).
  • To critically assess the clinical data for commonly used herbal agents in BPH treatment.

Main Methods:

  • A comprehensive literature search was performed using Medline and PubMed.
  • Key phytotherapeutic agents, including Serenoa repens, Pygeum africanum, Secale cereale, and Hypoxis rooperi, were selected for review.
  • Studies were analyzed for clinical data, study design, and potential confounders.

Main Results:

  • Initial studies suggested potential benefits of phytotherapy for BPH, but often had methodological limitations.
  • Confounders such as poor product standardization and inadequate study design were identified in early trials.
  • More recent, robust clinical trials have consistently shown no significant efficacy for phytotherapy in treating BPH compared to placebo.

Conclusions:

  • Despite historical optimism, current high-quality evidence indicates phytotherapy is not more effective than placebo for symptomatic BPH.
  • While generally safe, the widespread use of these agents for BPH lacks robust scientific validation.
  • The urologic community's initial encouragement has not been substantiated by contemporary research.